A Doctor's Note on Coronavirus

f t # e
Washington, November 18, 2020 | comments

November 18, 2020

Dear Friends,

It is vital that Congress understand how many labs have the required capacity and capability for conducting research on COVID-19 vaccines, therapeutics and diagnostics. To this end, I sent a letter to the Centers for Disease Control and Prevention (CDC) with Energy and Commerce Committee Republican Leader Greg Walden (R-OR) and Oversight and Investigations Subcommittee Republican Leader Brett Guthrie (R-KY) requesting that the CDC share full, updated data on domestic lab capacity with BioSafety Level 3 status.

National Updates
The Centers for Disease Control and Prevention published a fact sheet showing how CARES Act supplement resources are advancing public health data and surveillance systems, which have led to faster and more accurate case reporting.

  • The CDC updated considerations for breastfeeding women with suspected or confirmed COVID-19, reflecting evidence that breast milk is not a likely source of COVID-19 transmission.

The Food and Drug Administration issued an Emergency Use Authorization for the Lucira COVID-19 All-In-One Test Kit, the first diagnostic test that provides rapid results from self-collection at home.

  • FDA Commissioner Stephen Hahn released a statement regarding transparency of Emergency Use Authorizations relating to COVID-19.

The Centers for Medicare & Medicaid Services recognized over 1000 nursing homes where at least 50 percent of their staff completed CMS COVID-19 trainings on infection control, vaccine distribution, etc. A special congrats to the nursing homes in Texas for their diligence on this matter!

Duke University conducted a study on pooled testing of asymptomatic students on its campus. The study has contributed to a better understanding of how surveillance testing can be used to mitigate the spread of COVID-19 in congregate environments.

Until next time, this is your doctor’s note.

Congressman Michael C. Burgess, M.D.

f t # e